Liquidia Corporation (LQDA)

Currency in USD
56.690
-0.720(-1.25%)
Real-time Data·
LQDA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
55.85058.080
52 wk Range
22.31093.610
Key Statistics
Prev. Close
57.41
Open
57
Day's Range
55.85-58.08
52 wk Range
22.31-93.61
Volume
817.63K
Average Volume (3m)
3.49M
1-Year Change
102.1755%
Book Value / Share
-0.28
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LQDA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
63.875
Upside
+12.67%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Liquidia Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Analyst Ratings

6 Buy
2 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 63.875
(+12.67% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy76.00+34.06%-New CoverageNov 13, 2026
Raymond James
Buy77.00+35.83%53.00UpgradeNov 11, 2026
BofA Securities
Hold54.00-4.75%42.00MaintainNov 11, 2026
Wells Fargo
Hold40.00-29.44%33.00MaintainNov 11, 2026
BTIG
Buy87.00+53.47%70.00MaintainNov 10, 2026

Liquidia Corporation Earnings Call Summary for Q3/2026

  • Q3 revenue hit $225.3M, beating estimates by 5.2%; YUTREPIA sales surged 31% sequentially to $222.7M with strong PAH adoption momentum.
  • Posted $2.64 EPS loss vs. $0.90 profit forecast due to $389.7M one-time United Therapeutics patent settlement charge through April 2027.
  • Adjusted EBITDA rose to $140.5M for fifth straight quarter; gross margin held at 94% while SG&A fell to 26% of revenue, showing operating leverage.
  • Settlement removes litigation overhang but limits YUTREPIA label to PAH only; company says no capital raise needed to fund operations and payments.
  • October shipments reached record highs post-settlement; formal 2027 guidance delayed to January with SPRINT study launch expected by end of 2026.
Last Updated: 2026-11-10, 09:36 a/m
Read Full Transcript

Earnings

Latest Release
Nov 10, 2026
EPS / Forecast
-2.64 / 0.90
Revenue / Forecast
225.3M / 214.18M
EPS Revisions
Last 90 days

LQDA Income Statement

Compare LQDA to Peers and Sector

Metrics to compare
LQDA
Peers
Sector
Relationship
P/E Ratio
−54.0x−3.7x−0.2x
PEG Ratio
−2.17−0.170.00
Price/Book
−200.0x8.3x2.6x
Price / LTM Sales
8.2x2.3x2.8x
Upside (Analyst Target)
16.6%68.8%65.0%
Fair Value Upside
Unlock12.4%9.5%Unlock

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Employees
216

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
29.02M32.21%1.67B
Other Institutional Investors
45.32M50.30%2.60B
Public Companies & Retail Investors
15.76M17.49%904.87M
Total
90.11M100.00%5.17B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.11.97%10,788,586619,373
Farallon Capital Management, L.L.C.9.28%8,365,038480,237

People Also Watch

14.76
XP
-4.71%
64.83
ETON
+1.41%
414.29
ONC
-0.54%
45.13
ACMR
-5.88%
51.67
NSP
+2.35%

FAQ

What Is the Liquidia (LQDA) Stock Price Today?

The Liquidia stock price today is 56.690 USD.

What Stock Exchange Does Liquidia Trade On?

Liquidia is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Liquidia?

The stock symbol for Liquidia is "LQDA."

What Is the Liquidia Market Cap?

As of today, Liquidia market cap is 5.110B USD.

What Is Liquidia's Earnings Per Share (TTM)?

The Liquidia EPS (TTM) is -1.07.

When Is the Next Liquidia Earnings Date?

Liquidia will release its next earnings report on Mar 18, 2027.

From a Technical Analysis Perspective, Is LQDA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Liquidia Stock Split?

Liquidia has split 0 times.

How Many Employees Does Liquidia Have?

Liquidia has 216 employees.

What is the current trading status of Liquidia (LQDA)?

As of Nov 16, 2026, Liquidia (LQDA) is trading at a price of 56.690 USD, with a previous close of 57.410 USD. The stock has fluctuated within a day range of 55.850 USD to 58.080 USD, while its 52-week range spans from 22.310 USD to 93.610 USD.

What Is Liquidia (LQDA) Price Target According to Analysts?

The average 12-month price target for Liquidia is 63.875 USD, with a high estimate of 87 USD and a low estimate of 33 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +12.67% Upside potential.

What Is the LQDA Premarket Price?

LQDA's last pre-market stock price is 56.400 USD. The pre-market share volume is 11,310.000, and the stock has decreased by -1.010, or -1.760%.

What Is the LQDA After Hours Price?

LQDA's last after hours stock price is 57.000 USD, the stock has decreased by -0.410, or -0.710%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.